These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 12043951)

  • 1. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.
    Martinez MN; Amidon GL
    J Clin Pharmacol; 2002 Jun; 42(6):620-43. PubMed ID: 12043951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding
    B Shekhawat P; B Pokharkar V
    Acta Pharm Sin B; 2017 May; 7(3):260-280. PubMed ID: 28540164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food, gastrointestinal pH, and models of oral drug absorption.
    Abuhelwa AY; Williams DB; Upton RN; Foster DJ
    Eur J Pharm Biopharm; 2017 Mar; 112():234-248. PubMed ID: 27914234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal drug transporters: in vivo function and clinical importance.
    Kunta JR; Sinko PJ
    Curr Drug Metab; 2004 Feb; 5(1):109-24. PubMed ID: 14965254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The transporters of intestinal tract and their study methods].
    Liu ZH; Liu KX
    Yao Xue Xue Bao; 2011 Apr; 46(4):370-6. PubMed ID: 21751488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the Absorption of a Low Solubility Compound: Ciprofloxacin.
    Martinez M; Mistry B; Lukacova V; Polli J; Hoag S; Dowling T; Kona R; Fahmy R
    AAPS J; 2016 Jul; 18(4):886-97. PubMed ID: 27116024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
    Rinaki E; Valsami G; Macheras P
    Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.
    Hurst S; Loi CM; Brodfuehrer J; El-Kattan A
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):469-89. PubMed ID: 17696800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and Monte Carlo simulations in oral drug absorption.
    Dokoumetzidis A; Kosmidis K; Argyrakis P; Macheras P
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):200-5. PubMed ID: 15733215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.
    Amidon GL; Lennernäs H; Shah VP; Crison JR
    Pharm Res; 1995 Mar; 12(3):413-20. PubMed ID: 7617530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations.
    Martinez M; Amidon G; Clarke L; Jones WW; Mitra A; Riviere J
    Adv Drug Deliv Rev; 2002 Oct; 54(6):825-50. PubMed ID: 12363433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Lin X; Skolnik S; Chen X; Wang J
    Drug Metab Dispos; 2011 Feb; 39(2):265-74. PubMed ID: 21051535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
    Stuurman FE; Nuijen B; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2013 Jun; 52(6):399-414. PubMed ID: 23420518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.
    Aungst BJ
    J Pharm Sci; 1993 Oct; 82(10):979-87. PubMed ID: 8254497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.
    Nagar S; Korzekwa RC; Korzekwa K
    Mol Pharm; 2017 Sep; 14(9):3069-3086. PubMed ID: 28712300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
    Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
    Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.